All posts by Sandeep Bhat
Eyenuk’s logo was originally conceived back in early 2013 , to give the viewer the impression of staring at a “real” 3-dimensional eye, while giving it an orange hue to be consistent with the Eyenuk branding. The logo’s font was chosen to serve as a logo on its own when required. Our old logo has […]
Continue Reading »
LOS ANGELES, California, Oct. 2, 2018 – Eyenuk, Inc. announces its expansion into Germany with the adoption of EyeArt® artificial intelligence (AI) technology for the screening of diabetic retinopathy at Diabetes Center Mergentheim in Bad Mergentheim, Germany. The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic […]
Continue Reading »
A new study published in the international ‘Eye’ journal (Springer Nature) demonstrated very high sensitivity for detecting any diabetic retinopathy (95.8%) and sight-threatening diabetic retinopathy (99.1%) using EyeArt™ automated screening software with Remidio Fundus on Phone system. LOS ANGELES, CA, March 12, 2018 — Eyenuk, Inc., a leading developer of advanced clinically supported artificial intelligence […]
Continue Reading »
Eyenuk’s quality management system has been registered under the Medical Device Single Audit Program (“MDSAP”) as conforming to the requirements of ISO 13485:2003, after successfully completing an audit for the relevant quality management system requirements of the U.S. Food and Drug Administration and Health Canada. LOS ANGELES, CA, March 8, 2018 — Eyenuk, Inc., a […]
Continue Reading »
World Diabetes Day is the world’s largest diabetes awareness campaign. This year’s theme, Women and Diabetes, promotes the importance of access for all women with diabetes to education, treatment and care. Oslo University Hospital/University of Oslo in collaboration with Eyenuk Inc. recently highlighted the importance of early detection of diabetic retinopathy (DR) in women in […]
Continue Reading »
There is a lot of talk about the use of “deep learning” in the screening and identification of diabetic retinopathy (DR) lately. “Deep learning” is familiar to many in the tech industry, but is a relatively new concept in eye care. In very simple terms, deep learning is attempting to bring technology closer to artificial […]
Continue Reading »
Most people know that diabetes is about insulin abnormalities, whether it’s not producing enough insulin or body’s inability to recognize insulin and use it properly (in type 1 diabetes) or resistance to insulin (in type 2 diabetes). Quite a few know that the pancreas is involved in this, and are at least vaguely aware that […]
Continue Reading »
It starts out small enough. Your vision seems slightly blurred. At first you just think it’s a sign of increasing age; you notice that reading text is a little harder. But after a few months it seems to get worse. Eventually you go to your doctor, and he refers you to an ophthalmologist. After hearing […]
Continue Reading »
Eyenuk Inc. is presenting a validation study titled “Automated diabetic retinopathy screening: large-scale study on consecutive patient visits in a primary care setting” at the 52nd EASD Annual Meeting in Munich, Germany. Details are as indicated below Venue: Meyerhof Hall, ICM Messe München, Messegelände, 81823 München, Germany Presenter: Kaushal Solanki, Ph.D Scheduled time: Wednesday, September 14, 2016, 14:30 – 14:45 Session: […]
Continue Reading »
Eyenuk, Inc. will be showcasing its CE marked EyeArt™ fully-automated DR screening product at the 52nd EASD Annual Meeting in Munich, Germany from 12-16 September, 2016. Come visit our booth at the ICM Messe München, Messegelände, 81823 München, Germany Hall B, Booth B.02A (click map to view the interactive version)
Continue Reading »© Copyright 2010-2019, Eyenuk Inc.